NZX Governance Explorer

How Promisia Healthcare Limited makes money

Where PHL’s revenue went in FY2024: operating costs, depreciation, interest and tax, and what was left as net profit. Built from the income statement in the filed annual report, and drawn only when the figures reconcile with each other. PHL company profile

How Promisia Healthcare Limited makes money — FY2024

Revenue $26.3m · EBITDA $3.6m (13.8% of revenue) · Net profit $1.6m (6.2% of revenue) · Financial year ending March (from the issuer record)

Promisia Healthcare Limited (PHL) FY2024: where revenue of $26.3m wentRevenue → EBITDA: $3.6mRevenue → Operating costs (net of other income): $22.7mEBITDA → EBIT: $2.8mEBITDA → Depreciation & amortisation: $802kEBIT → Net profit: $1.6mEBIT → Interest: $1.2mOther items (net gain) → Interest: $1.5mOther items (net gain) → Income tax: $2.0mRevenue: $26.3mRevenue$26.3mEBITDA: $3.6mEBITDA$3.6mOperating costs (net of other income): $22.7m (derived)Operating costs (net ofother income)$22.7m · derivedEBIT: $2.8m (derived)EBIT$2.8m · derivedDepreciation & amortisation: $802kDepreciation &amortisation$802kOther items (net gain): $3.4m (balancing item)Other items (net gain)$3.4m · balancingNet profit: $1.6mNet profit$1.6mInterest: $2.7mInterest$2.7mIncome tax: $2.0mIncome tax$2.0m

Band widths are proportional to NZD amounts. Dashed outlines mark derived figures; the hatched node is a balancing item (net profit less every line above it).

Promisia Healthcare Limited FY2024 figures used in the chart
FY2024AmountStatusNote
Revenue$26.3mReported
Operating costs (net of other income)−$22.7mDerived *Reported operating expenses $18.9m do not reconcile; not used.
EBITDA$3.6mReported
Depreciation & amortisation−$802kReported
EBIT$2.8mDerived *Reported EBIT $0.9m does not reconcile to EBITDA − D&A.
Interest (net finance costs)−$2.7mReported
Income tax−$2.0mReported
Other items (net gain)+$3.4mBalancing item *Net profit less the lines above; covers fair-value movements, impairments, associates and anything else not itemised.
Net profit$1.6mReported
  • * ebit: $2.8m = EBITDA − D&A (reported EBIT $0.9m differs; the gap falls into Other items)
  • * operating costs: $22.7m = Revenue − EBITDA
Checks run on these figures (6)
  • Passed: Revenue is within the scale of a column stored in thousands.
  • Passed: Revenue in the income statement ($26.3m) vs the summary table ($26.3m): agree within 2%.
  • Not met: EBITDA − D&A = $2.8m vs reported EBIT $0.9m: does not reconcile.
  • Not met: Reported operating expenses ($18.9m) leave $7.3m, not EBITDA of $3.6m (gap $3.7m); costs derived as revenue minus operating profit instead. No split is shown.
  • Passed: Balancing item $3.4m is 13.1% of revenue (limit 25%).
  • Not met: No operating segments recorded for this year.

Figures extracted automatically from the annual report; check against the report. NZD thousands as stored, shown in millions. Source: annual_report_pdf · method: claude_haiku_pdf · extracted 7 March 2026.

Annual report: FY24 Promisia Annual Report (PDF, NZX)

EBITDA bridge, FY2023 → FY2024

What moved EBITDA between the two years: the change in revenue, less the change in operating costs (revenue less EBITDA, net of other income; not a reported line). The costs are one net figure; no split by type is held, so none is shown.

PHL EBITDA bridge FY2023 to FY2024FY2023 EBITDA: $3.6m$3.6mFY2023 EBITDARevenue change: +$2.4m+$2.4mRevenue changeCost change (derived): −$2.4m−$2.4mCost change (derived)FY2024 EBITDA: $3.6m$3.6mFY2024 EBITDA
PHL EBITDA bridge FY2023 to FY2024: figures
StepFY2023FY2024Effect on EBITDAStatus
FY2023 EBITDA$3.6m$3.6mAs charted
Revenue$23.9m$26.3m+$2.4mReported
Operating costs (net, derived)$20.3m$22.7m−$2.4mDerived: revenue − EBITDA
FY2024 EBITDA$3.6m$3.6mAs charted

$3.6m +$2.4m −$2.4m = $3.6m, which equals FY2024 EBITDA of $3.6m. EBITDA is the figure stored from each statement; companies that headline an adjusted measure (EBITDAF, underlying EBITDA) can report a different number.

What changed from FY2023 to FY2024

MeasureFY2023FY2024ChangeChange %
Revenue$23.9m$26.3m+$2.4m+10.1%
EBITDA$3.6m$3.6m+$57k+1.6%
Net profit$692k$1.6m+$943k+136.3%
EBITDA margin15.0%13.8%−1.2 pts—
Net margin2.9%6.2%+3.3 pts—

Both years passed the same checks. Margins are shares of revenue; their change is in percentage points. n/m = not meaningful (prior-year figure at or below zero). Each year holds the figures from its own annual report; restated comparatives are not applied.

Margins over time

EBITDA, EBIT and net profit as a share of revenue for each year whose figures passed the checks (5 of 9 years from FY2017). The shaded line is the median of 11 other listed Healthcare operating companies, using each one’s same financial year where it passed the checks; the number of companies in each median is in the table. Gaps are years that were not charted.

EBITDA margin
PHL ebitda margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY25FY2017: not charted — operating lossFY2018: not charted — operating lossFY2019: not charted — operating lossFY2020: not charted — no annual statement on fileFY2021: PHL 16.8%; peer median 19.1% (3)FY2022: PHL 23.7%; peer median 22.4% (4)FY2023: PHL 15.0%; peer median 11.4% (5)FY2024: PHL 13.8%; peer median 12.2% (7)FY2025: PHL 13.5%; peer median 13.2% (7)
EBIT margin
PHL ebit margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY25FY2017: not charted — operating lossFY2018: not charted — operating lossFY2019: not charted — operating lossFY2020: not charted — no annual statement on fileFY2021: PHL 10.5%; peer median 9.5% (5)FY2022: PHL 19.4%; peer median 18.3% (4)FY2023: PHL 11.5%; peer median 6.9% (5)FY2024: PHL 10.8%; peer median 6.4% (7)FY2025: PHL 12.2%; peer median 8.8% (7)
Net margin
PHL net margin by financial year, with peer median0%20%40%FY17FY18FY20FY22FY24FY25FY2017: not charted — operating lossFY2018: not charted — operating lossFY2019: not charted — operating lossFY2020: not charted — no annual statement on fileFY2021: PHL 0.4%; peer median 3.7% (5)FY2022: PHL 10.7%; peer median 13.7% (4)FY2023: PHL 2.9%; peer median 6.2% (5)FY2024: PHL 6.2%; peer median 3.1% (7)FY2025: PHL 22.0%; peer median 5.5% (7)

PHL   peer median   below the axis: year not charted (reason in the table). All panels share one scale.

PHL margins by year with peer medians
YearEBITDA margin: PHL · peer median (n)EBIT margin: PHL · peer median (n)Net margin: PHL · peer median (n)Note
FY2017—— (1)—33.0% (2)—22.5% (2)Not charted: operating loss
FY2018—8.6% (3)—16.6% (4)—11.6% (4)Not charted: operating loss
FY2019—11.7% (4)—7.2% (5)—3.9% (5)Not charted: operating loss
FY2020—9.3% (4)—12.8% (6)—7.9% (6)Not charted: no annual statement on file
FY202116.8%19.1% (3)10.5%9.5% (5)0.4%3.7% (5)
FY202223.7%22.4% (4)19.4%18.3% (4)10.7%13.7% (4)
FY202315.0%11.4% (5)11.5%6.9% (5)2.9%6.2% (5)
FY202413.8%12.2% (7)10.8%6.4% (7)6.2%3.1% (7)
FY202513.5%13.2% (7)12.2%8.8% (7)22.0%5.5% (7)

Peer medians use only peer-years that passed the same checks; a median of fewer than two companies is not shown. Years are grouped by financial-year label, and year-end months differ between companies.

Not yet available: where the cash goes (operating cash flow to capex, dividends and debt) and underlying versus reported earnings. The figures they need are not yet validated.

Years not charted

These years are on file but their figures did not pass the checks, so no chart is drawn for them.

  • FY2019: EBIT is -$1.7m. This layout does not draw an operating loss.
  • FY2018: EBITDA is -$2.3m. This layout draws revenue flowing into profit and does not draw an operating loss.
  • FY2017: EBITDA is -$0.4m. This layout draws revenue flowing into profit and does not draw an operating loss.
  • FY2016: EBITDA is -$0.4m. This layout draws revenue flowing into profit and does not draw an operating loss.
  • FY2015: Figures were not read from a filed annual report (source: not recorded).

All companies with a chart

Data sourced from NZX company annual reports (income statements). Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz.

For informational purposes only. Not investment advice.

Get NZX governance insights in your inbox

Weekly digest of board changes, insider trades, and market signals. No spam. Unsubscribe anytime.